AI robot performs gallbladder surgery autonomously
For the first time, an autonomous surgical robot completed a key phase of gallbladder removal on a lifelike patient. It worked independently and adapted in real time to unexpected challenges.
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my CYBERGUY.COM/NEWSLETTER
Unlike previous surgical robots that followed rigid, pre-programmed instructions, the new system, named Surgical Robot Transformer-Hierarchy (SRT-H), was trained using hours of surgery videos. Researchers at Johns Hopkins University fed the robot visual data and captions describing each step of the procedure. This approach allowed SRT-H to learn the sequence and nuances of gallbladder surgery, including identifying ducts and arteries, placing clips and making precise cuts.
What sets SRT-H apart is its ability to respond to voice commands from the surgical team. For example, the robot can understand instructions like "grab the gallbladder head" or "move the left arm a bit to the left." This interactive feedback loop enables the robot to learn and self-correct, much like a surgical resident guided by a mentor.
During trials, SRT-H demonstrated remarkable adaptability. It performed the 17-step gallbladder removal process with 100% accuracy, even when researchers altered its starting position or changed the appearance of tissues using blood-like dyes. The robot's performance matched that of skilled human surgeons, handling unexpected scenarios with composure and precision.
"This advancement moves us from robots that can execute specific surgical tasks to robots that truly understand surgical procedures," said Axel Krieger, lead researcher at Johns Hopkins University.
Traditional surgical robots have made procedures less invasive, but they still rely heavily on human control. The autonomous surgical robot represents a step forward by combining mechanical precision with the ability to adapt and make decisions in real time. This technology could one day lead to fully autonomous surgeries, potentially improving outcomes and expanding access to high-quality surgical care worldwide.
The success of SRT-H in gallbladder surgery is just the beginning. Researchers plan to train the robot on a wider range of procedures and further enhance its capabilities. The ultimate goal is a robot that can perform entire surgeries autonomously, adapting to the unique anatomy and challenges of each patient.
If you've ever faced a long wait for surgery or worried about human error in the operating room, this breakthrough could directly affect your care. Autonomous surgical robots like SRT-H promise faster procedures, fewer complications and better access, especially in rural or underserved areas. With their ability to learn from real surgeries and adjust in real time, these robots could support overworked surgical teams and help reduce burnout.
For patients, that means more consistent outcomes and shorter recovery times. While fully autonomous surgery isn't available in U.S. hospitals just yet, the technology is moving fast. What happened in a research lab today could be part of your next hospital visit sooner than you think.
The arrival of autonomous surgical robots is changing medicine fast. By combining artificial intelligence, machine learning and real-time feedback, these robots are ready to transform the operating room. As this technology improves, the gap between human skill and robotic precision will continue to shrink. This shift promises a future where surgery is safer and more efficient than ever before.
If a robot can perform surgery with the skill of a top surgeon, would you trust an AI machine to operate on you or your loved ones? Let us know by writing us at Cyberguy.com/Contact
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my CYBERGUY.COM/NEWSLETTER
Copyright 2025 CyberGuy.com. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
29 minutes ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
MrFluffyFriend Launches XXXXL Calming Dog Bed for Large and Anxious Dogs
Over 600,000 dogs sleep better already — now available in 48 inch (120cm) & 56 inch (140cm) with up to 60% off and free shipping on Image by MrFluffyFriend LOS ANGELES, July 27, 2025 (GLOBE NEWSWIRE) -- MrFluffyFriend, a fast-growing U.S. pet wellness brand known for its calming products, announces the launch of its XXXXL Calming Dog Bed, specially designed for large breeds and dogs prone to anxiety. The oversized beds, now available in 120cm and 140cm, offer unmatched comfort and emotional relief thanks to premium materials and calming features rooted in behavioral science. Made with ultra-soft vegan faux fur, deep orthopedic padding, and a raised rim for added head and neck support, the XXXXL Calming Bed creates a soothing nest-like environment that helps dogs feel safe, supported, and calm — especially during fireworks, thunderstorms, or when left home alone. 'We've helped over 600,000 dogs sleep better with our calming beds,' says a MrFluffyFriend spokesperson. 'Our community asked for something big enough for their Labradors, Golden Retrievers, Huskies — and we listened. This launch is all about showing that big dogs deserve big comfort, too.' According to veterinarians, over 70% of dogs experience anxiety at some point, which can lead to restlessness, whining, and destructive behavior. MrFluffyFriend's calming design mimics a mother's touch, helping to trigger the release of serotonin and reduce stress naturally. Key Features: Sizes: XXXL (48 in / 120 cm) and XXXXL (56 in / 140 cm) Raised rim for orthopedic support and security Ultra-soft faux fur mimics a mother's touch Machine washable cover + water-resistant, non-slip base Hypoallergenic and pet-safe materials Ideal for large breeds and multi-dog households The launch is accompanied by a limited-time offer of up to 60% off, free shipping across the U.S., and a 30-day risk-free trial, making it easier than ever for pet parents to try the product. Early feedback has been overwhelmingly positive, with customers praising the bed's luxurious size, fluffiness, and noticeable calming effect. Some report their dogs sleep longer, bark less, and even retreat to the bed during stressful moments like vet visits or fireworks. About MrFluffyFriend Founded with a mission to help pets feel safe, calm, and loved, MrFluffyFriend is a pet lifestyle brand trusted by dog lovers in over 25 countries. From calming beds to wellness accessories, every product is developed with science-backed design and premium materials to ensure pets thrive — emotionally and physically. Learn more at Media Contact: Thomas, H. info@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
USA Swimming confirms stomach bug impacting team at worlds
USA Swimming has confirmed reports that some team members competing in the World Aquatics Championships in Singapore were recovering from acute gastroenteritis, US public broadcaster NPR reported. USA Swimming senior communications director Nikki Warner said in a statement cited by NPR that "those experiencing symptoms" were receiving treatment, without saying which swimmers were affected or how they got sick. The team's medical staff was also "advising the team on further preventative and recovery measures," Warner added. The team is "planning to race and perform to the best of our ability for the rest of the meet," Warner said, according to NPR. Acute gastroenteritis, an inflammation of the stomach and intestines, is usually caused by viruses such as Norovirus or bacteria such as On Saturday, Paris 100 metre butterfly gold medallist Torri Huske did not swim the 100m butterfly "to prioritize her efforts in the 4x100m freestyle relay," USA Swimming said. The relay, which had been favoured to win and was anchored by Huske, came second behind Australia on Sunday evening. Claire Weinstein also pulled out of the 400 metre freestyle. Several US swimmers performed below expectations on Sunday and on Monday morning.
